How do the ALTTO trial findings influence your choice of adjuvant endocrine therapy (AI with or without ovarian function suppression versus SERM-based therapy) for patients with HR+/HER2+ early breast cancer?  

The major takeaway is that endocrine therapy works for HER2+ breast cancer, although the magnitude of the benefit may not be as large as for ER+/HER2- BC. Thus, OFS will contribute to efficacy in a way similar to that of the TEXT/SOFT trial. Because of the higher toxicity associated with OFS, the ab...